Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30995328 | 1.00 | TBK1 (0.40) | TBK1TP53LMNATLR9THRB | |
| SCHEMBL29318877 | 0.90 | F10 (0.36) | — | |
| SCHEMBL30995356 | 0.90 | F10 (0.36) | — | |
| SCHEMBL27392867 | 0.88 | DDB1 (0.36) | TBK1TP53LMNATLR9THRB | |
| SCHEMBL29318390 | 0.83 | TLR9 (0.37) | TBK1TP53LMNATLR9TDP1 | |
| SCHEMBL30995287 | 0.83 | TLR9 (0.37) | TBK1TP53LMNATLR9TDP1 | |
| SCHEMBL27213776 | 0.83 | TLR9 (0.37) | TBK1TP53LMNATLR9TDP1 | |
| SCHEMBL29319793 | 0.80 | GPR119 (0.37) | TBK1TP53LMNATLR9THRB | |
| SCHEMBL30995379 | 0.80 | GPR119 (0.37) | TBK1TP53LMNATLR9THRB | |
| SCHEMBL27392873 | 0.79 | F10 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | TBK1 3561/4885TP53 1737/4885LMNA 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.